SGIOF - European advisory group backs ViiV's cabotegravir and rilpivirine regimen in HIV

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Viiv Healthcare's Vocabria (cabotegravir injection and tablets) in combination with Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), for the treatment of HIV-1 infection  who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) and not resistant to either drug.ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK), Pfizer (PFE) and Shionogi (SGIOF)

For further details see:

European advisory group backs ViiV's cabotegravir and rilpivirine regimen in HIV